{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:49:10Z","timestamp":1770508150247,"version":"3.49.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,5,6]],"date-time":"2014-05-06T00:00:00Z","timestamp":1399334400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s40268-014-0045-9","type":"journal-article","created":{"date-parts":[[2014,5,5]],"date-time":"2014-05-05T10:02:15Z","timestamp":1399284135000},"page":"113-123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Correlation Between Trough Plasma Dabigatran Concentrations and Estimates of Glomerular Filtration Rate Based on Creatinine and Cystatin C"],"prefix":"10.1007","volume":"14","author":[{"given":"Paul K. L.","family":"Chin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F. B.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary C.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca L.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berit P.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray L.","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan J.","family":"Begg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,6]]},"reference":[{"issue":"21","key":"45_CR1","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","volume":"33","author":"AJ Camm","year":"2012","unstructured":"Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719\u201347. doi: 10.1093\/eurheartj\/ehs253 .","journal-title":"Eur Heart J"},{"issue":"2","key":"45_CR2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cjca.2012.01.021","volume":"28","author":"AC Skanes","year":"2012","unstructured":"Skanes AC, Healey JS, Cairns JA, Dorian P, Gillis AM, McMurtry MS, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate\/rhythm control. Can J Cardiol. 2012;28(2):125\u201336. doi: 10.1016\/j.cjca.2012.01.021 .","journal-title":"Can J Cardiol"},{"issue":"2 Suppl","key":"45_CR3","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","volume":"141","author":"W Ageno","year":"2012","unstructured":"Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S\u201388S. doi: 10.1378\/chest.11-2292 .","journal-title":"Chest"},{"issue":"4","key":"45_CR4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","volume":"63","author":"PA Reilly","year":"2014","unstructured":"Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63(4):321\u20138. doi: 10.1016\/j.jacc.2013.07.104 .","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"45_CR5","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1160\/TH11-10-0718","volume":"107","author":"MV Huisman","year":"2012","unstructured":"Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost. 2012;107(5):838\u201347. doi: 10.1160\/TH11-10-0718 .","journal-title":"Thromb Haemost"},{"key":"45_CR6","doi-asserted-by":"crossref","unstructured":"Brunet A, Hermabessiere S, Benain X. Pharmacokinetic and pharmacodynamic interaction of dronedarone and dabigatran in healthy subjects. Eur Heart J. 2011;32(Suppl. 1):313\u2013631. doi: 10.1093\/eurheartj\/ehr323 .","DOI":"10.1093\/eurheartj\/ehr323"},{"issue":"3","key":"45_CR7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00228-012-1304-8","volume":"69","author":"S Hartter","year":"2013","unstructured":"Hartter S, Sennewald R, Schepers C, Baumann S, Fritsch H, Friedman J. Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. Eur J Clin Pharmacol. 2013;69(3):327\u201339. doi: 10.1007\/s00228-012-1304-8 .","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"45_CR8","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2125.2012.04453.x","volume":"75","author":"S Hartter","year":"2013","unstructured":"Hartter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa((R))) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol. 2013;75(4):1053\u201362. doi: 10.1111\/j.1365-2125.2012.04453.x .","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"45_CR9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/bcp.12055","volume":"76","author":"X Delavenne","year":"2013","unstructured":"Delavenne X, Ollier E, Basset T, Bertoletti L, Accassat S, Garcin A, et al. A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Br J Clin Pharmacol. 2013;76(1):107\u201313. doi: 10.1111\/bcp.12055 .","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"45_CR10","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2125.2012.04218.x","volume":"74","author":"S Hartter","year":"2012","unstructured":"Hartter S, Koenen-Bergmann M, Sharma A, Nehmiz G, Lemke U, Timmer W, et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol. 2012;74(3):490\u2013500. doi: 10.1111\/j.1365-2125.2012.04218.x .","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"45_CR11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0091270005274550","volume":"45","author":"J Stangier","year":"2005","unstructured":"Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45(5):555\u201363. doi: 10.1177\/0091270005274550 .","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"45_CR12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200847010-00005","volume":"47","author":"J Stangier","year":"2008","unstructured":"Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47(1):47\u201359. doi: 10.2165\/00003088-200847010-00005 .","journal-title":"Clin Pharmacokinet"},{"issue":"13","key":"45_CR13","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCULATIONAHA.112.001233","volume":"127","author":"G Pare","year":"2013","unstructured":"Pare G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127(13):1404\u201312. doi: 10.1161\/CIRCULATIONAHA.112.001233 .","journal-title":"Circulation"},{"key":"45_CR14","unstructured":"US Food and Drug Administration. Briefing information for the September 20, 2010, meeting of the cardiovascular and renal drugs advisory committee; 2010. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM247244.pdf . Accessed 9 Sep 2013."},{"issue":"2","key":"45_CR15","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","volume":"36","author":"S Blech","year":"2008","unstructured":"Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386\u201399. doi: 10.1124\/dmd.107.019083 .","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"45_CR16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","volume":"49","author":"J Stangier","year":"2010","unstructured":"Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49(4):259\u201368. doi: 10.2165\/11318170-000000000-00000 .","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"45_CR17","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1124\/dmd.110.033696","volume":"38","author":"T Ebner","year":"2010","unstructured":"Ebner T, Wagner K, Wienen W. Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010;38(9):1567\u201375. doi: 10.1124\/dmd.110.033696 .","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"45_CR18","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2125.2012.04266.x","volume":"74","author":"PK Chin","year":"2012","unstructured":"Chin PK, Vella-Brincat JW, Barclay ML, Begg EJ. Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles? Br J Clin Pharmacol. 2012;74(5):734\u201340. doi: 10.1111\/j.1365-2125.2012.04266.x .","journal-title":"Br J Clin Pharmacol"},{"key":"45_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"KDIGO","year":"2012","unstructured":"KDIGO. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1\u2013138.","journal-title":"Kidney Int Suppl"},{"key":"45_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"KDIGO","year":"2013","unstructured":"KDIGO. KDIGO clinical practice guideline for chronic kidney disease. Kidney Int Suppl. 2013;3:1\u2013150.","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"45_CR21","first-page":"75","volume":"32","author":"CM Florkowski","year":"2011","unstructured":"Florkowski CM, Chew-Harris JS. Methods of estimating GFR\u2014different equations including CKD-EPI. Clin Biochem Rev. 2011;32(2):75\u20139.","journal-title":"Clin Biochem Rev"},{"issue":"1","key":"45_CR22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341.","journal-title":"Nephron"},{"issue":"11","key":"45_CR23","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ki.2011.322","volume":"80","author":"GR Matzke","year":"2011","unstructured":"Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, et al. Drug dosing consideration in patients with acute and chronic kidney disease\u2014a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(11):1122\u201337. doi: 10.1038\/ki.2011.322 .","journal-title":"Kidney Int"},{"issue":"9","key":"45_CR24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312. (pii: 150\/9\/604).","journal-title":"Ann Intern Med"},{"issue":"11","key":"45_CR25","doi-asserted-by":"crossref","first-page":"785","DOI":"10.7326\/0003-4819-156-11-201203200-00391","volume":"156","author":"A Earley","year":"2012","unstructured":"Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med. 2012;156(11):785\u201395. doi: 10.1059\/0003-4819-156-6-201203200-00391 .","journal-title":"Ann Intern Med"},{"issue":"1383","key":"45_CR26","first-page":"97","volume":"126","author":"OK Howey","year":"2013","unstructured":"Howey OK, Chin PK. Usage of renal function equations to guide prescribing in general medicine. N Z Med J. 2013;126(1383):97\u20139.","journal-title":"N Z Med J"},{"issue":"5","key":"45_CR27","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.0954-6820.1985.tb08880.x","volume":"218","author":"A Grubb","year":"1985","unstructured":"Grubb A, Simonsen O, Sturfelt G, Truedsson L, Thysell H. Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand. 1985;218(5):499\u2013503.","journal-title":"Acta Med Scand"},{"issue":"11","key":"45_CR28","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1515\/CCLM.2010.318","volume":"48","author":"A Grubb","year":"2010","unstructured":"Grubb A, Blirup-Jensen S, Lindstrom V, Schmidt C, Althaus H, Zegers I, et al. First certified reference material for cystatin C in human serum ERM-DA471\/IFCC. Clin Chem Lab Med. 2010;48(11):1619\u201321. doi: 10.1515\/CCLM.2010.318 .","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"45_CR29","first-page":"47","volume":"29","author":"JS Chew","year":"2008","unstructured":"Chew JS, Saleem M, Florkowski CM, George PM. Cystatin C\u2014a paradigm of evidence based laboratory medicine. Clin Biochem Rev. 2008;29(2):47\u201362.","journal-title":"Clin Biochem Rev"},{"issue":"1","key":"45_CR30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20\u20139. doi: 10.1056\/NEJMoa1114248 .","journal-title":"N Engl J Med"},{"issue":"7","key":"45_CR31","doi-asserted-by":"crossref","first-page":"471","DOI":"10.7326\/0003-4819-157-7-201210020-00003","volume":"157","author":"ES Schaeffner","year":"2012","unstructured":"Schaeffner ES, Ebert N, Delanaye P, Frei U, Gaedeke J, Jakob O, et al. Two novel equations to estimate kidney function in persons aged 70\u00a0years or older. Ann Intern Med. 2012;157(7):471\u201381. doi: 10.7326\/0003-4819-157-7-201210020-00003 .","journal-title":"Ann Intern Med"},{"issue":"7","key":"45_CR32","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/imj.12170","volume":"43","author":"PK Chin","year":"2013","unstructured":"Chin PK, Vella-Brincat JW, Walker SL, Barclay ML, Begg EJ. Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital. Intern Med J. 2013;43(7):778\u201383. doi: 10.1111\/imj.12170 .","journal-title":"Intern Med J"},{"issue":"2","key":"45_CR33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263\u201372. doi: 10.1378\/chest.09-1584 .","journal-title":"Chest"},{"issue":"5","key":"45_CR34","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093\u2013100. doi: 10.1378\/chest.10-0134 .","journal-title":"Chest"},{"issue":"3","key":"45_CR35","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5694\/j.1326-5377.2005.tb06958.x","volume":"183","author":"TH Mathew","year":"2005","unstructured":"Mathew TH. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: a position statement. Med J Aust. 2005;183(3):138\u201341.","journal-title":"Med J Aust"},{"issue":"5","key":"45_CR36","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/clpt.2009.124","volume":"86","author":"LA Stevens","year":"2009","unstructured":"Stevens LA, Levey AS. Use of the MDRD study equation to estimate kidney function for drug dosing. Clin Pharmacol Ther. 2009;86(5):465\u20137. doi: 10.1038\/clpt.2009.124 .","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"45_CR37","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/clpt.2009.187","volume":"86","author":"WJ Spruill","year":"2009","unstructured":"Spruill WJ, Wade WE, Cobb HH 3rd. Continuing the use of the Cockcroft\u2013Gault equation for drug dosing in patients with impaired renal function. Clin Pharmacol Ther. 2009;86(5):468\u201370. doi: 10.1038\/clpt.2009.187 .","journal-title":"Clin Pharmacol Ther"},{"issue":"Pt 6","key":"45_CR38","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1177\/0004563213492320","volume":"50","author":"PK Chin","year":"2013","unstructured":"Chin PK, Florkowski CM, Begg EJ. The performances of the Cockcroft\u2013Gault, modification of diet in renal disease study and chronic kidney disease epidemiology collaboration equations in predicting gentamicin clearance. Ann Clin Biochem. 2013;50(Pt 6):546\u201357. doi: 10.1177\/0004563213492320 .","journal-title":"Ann Clin Biochem"},{"issue":"17","key":"45_CR39","first-page":"1098","volume":"317","author":"RD Mosteller","year":"1987","unstructured":"Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098. doi: 10.1056\/NEJM198710223171717 .","journal-title":"N Engl J Med"},{"issue":"5","key":"45_CR40","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1053\/j.ajkd.2012.11.048","volume":"61","author":"E Selvin","year":"2013","unstructured":"Selvin E, Juraschek SP, Eckfeldt J, Levey AS, Inker LA, Coresh J. Within-person variability in kidney measures. Am J Kidney Dis. 2013;61(5):716\u201322. doi: 10.1053\/j.ajkd.2012.11.048 .","journal-title":"Am J Kidney Dis"},{"issue":"Pt 1","key":"45_CR41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1258\/acb.2012.011241","volume":"50","author":"JS Chew-Harris","year":"2013","unstructured":"Chew-Harris JS, Florkowski CM, George PM, Elmslie JL, Endre ZH. The relative effects of fat versus muscle mass on cystatin C and estimates of renal function in healthy young men. Ann Clin Biochem. 2013;50(Pt 1):39\u201346. doi: 10.1258\/acb.2012.011241 .","journal-title":"Ann Clin Biochem"},{"issue":"3","key":"45_CR42","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1053\/j.ajkd.2013.03.027","volume":"62","author":"MG Shlipak","year":"2013","unstructured":"Shlipak MG, Mattes MD, Peralta CA. Update on cystatin C: incorporation into clinical practice. Am J Kidney Dis. 2013;62(3):595\u2013603. doi: 10.1053\/j.ajkd.2013.03.027 .","journal-title":"Am J Kidney Dis"},{"key":"45_CR43","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jpba.2011.09.018","volume":"58","author":"X Delavenne","year":"2012","unstructured":"Delavenne X, Moracchini J, Laporte S, Mismetti P, Basset T. UPLC MS\/MS assay for routine quantification of dabigatran\u2014a direct thrombin inhibitor\u2014in human plasma. J Pharm Biomed Anal. 2012;58:152\u20136. doi: 10.1016\/j.jpba.2011.09.018 .","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"45_CR44","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0003-2697(88)90047-4","volume":"174","author":"TA Ciulla","year":"1988","unstructured":"Ciulla TA, Sklar RM, Hauser SL. A simple method for DNA purification from peripheral blood. Anal Biochem. 1988;174(2):485\u20138.","journal-title":"Anal Biochem"},{"issue":"3","key":"45_CR45","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559\u201375. doi: 10.1086\/519795 .","journal-title":"Am J Hum Genet"},{"issue":"1","key":"45_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinbiochem.2004.09.025","volume":"38","author":"G Filler","year":"2005","unstructured":"Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A. Cystatin C as a marker of GFR\u2014history, indications, and future research. Clin Biochem. 2005;38(1):1\u20138. doi: 10.1016\/j.clinbiochem.2004.09.025 .","journal-title":"Clin Biochem"},{"issue":"2","key":"45_CR47","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/MBC.0b013e32834f1b0c","volume":"23","author":"J Stangier","year":"2012","unstructured":"Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23(2):138\u201343. doi: 10.1097\/MBC.0b013e32834f1b0c .","journal-title":"Blood Coagul Fibrinolysis"},{"key":"45_CR48","unstructured":"Boehringer Ingelheim Pharma GmbH & Co. KG. Pradaxa. Summary of Product Characteristics. European Medicines Agency. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf . Accessed 5 Jan 2014."},{"issue":"3","key":"45_CR49","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2125.2011.04089.x","volume":"73","author":"EJ Begg","year":"2012","unstructured":"Begg EJ, Chin PK. A unified pharmacokinetic approach to individualized drug dosing. Br J Clin Pharmacol. 2012;73(3):335\u20139. doi: 10.1111\/j.1365-2125.2011.04089.x .","journal-title":"Br J Clin Pharmacol"},{"key":"45_CR50","doi-asserted-by":"crossref","unstructured":"Hellden A, Odar-Cederlof I, Nilsson G, Sjoviker S, Soderstrom A, Euler M et al. Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly. BMJ Open. 2013;3(4). doi: 10.1136\/bmjopen-2013-002686 .","DOI":"10.1136\/bmjopen-2013-002686"},{"issue":"9","key":"45_CR51","doi-asserted-by":"crossref","first-page":"e003343","DOI":"10.1136\/bmjopen-2013-003343","volume":"3","author":"PK MacCallum","year":"2013","unstructured":"MacCallum PK, Mathur R, Hull SA, Saja K, Green L, Morris JK, et al. Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study. BMJ Open. 2013;3(9):e003343. doi: 10.1136\/bmjopen-2013-003343 .","journal-title":"BMJ Open"},{"issue":"1357","key":"45_CR52","first-page":"148","volume":"125","author":"SB Duffull","year":"2012","unstructured":"Duffull SB, Wright DF, Al-Sallami HS, Zufferey PJ, Faed JM. Dabigatran: rational dose individualisation and monitoring guidance is needed. N Z Med J. 2012;125(1357):148\u201354.","journal-title":"N Z Med J"},{"issue":"9","key":"45_CR53","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.113.003628","volume":"129","author":"Z Hijazi","year":"2014","unstructured":"Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014;129(9):961\u201370. doi: 10.1161\/CIRCULATIONAHA.113.003628 .","journal-title":"Circulation"},{"key":"45_CR54","doi-asserted-by":"crossref","unstructured":"Chin PK, Wright DF, Patterson DM, Doogue MP, Begg EJ. A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol. 2014. doi: 10.1111\/bcp.12364 .","DOI":"10.1111\/bcp.12364"},{"issue":"2","key":"45_CR55","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0026-895X(25)08713-9","volume":"49","author":"EG Schuetz","year":"1996","unstructured":"Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996;49(2):311\u20138.","journal-title":"Mol Pharmacol"},{"issue":"12","key":"45_CR56","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/0091270008324179","volume":"48","author":"J Stangier","year":"2008","unstructured":"Stangier J, Stahle H, Rathgen K, Roth W, Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. 2008;48(12):1411\u20139. doi: 10.1177\/0091270008324179 .","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"45_CR57","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","volume":"64","author":"J Stangier","year":"2007","unstructured":"Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292\u2013303. doi: 10.1111\/j.1365-2125.2007.02899.x .","journal-title":"Br J Clin Pharmacol"},{"key":"45_CR58","unstructured":"US Food and Drug Administration. Guidance for industry: bioanalytical method validation; 2001. http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm070107.pdf . Accessed 6 April 2013."},{"key":"45_CR59","unstructured":"Boehringer Ingelheim (N.Z.) Limited. Pradaxa: New Zealand Datasheet. Medsafe; 2013. http:\/\/www.medsafe.govt.nz\/profs\/Datasheet\/p\/Pradaxacap.pdf . Accessed 28 Oct 2013."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-014-0045-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-014-0045-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-014-0045-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T17:57:50Z","timestamp":1746208670000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-014-0045-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,6]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["45"],"URL":"https:\/\/doi.org\/10.1007\/s40268-014-0045-9","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,6]]}}}